EP4577212A1 — Methods of treating uveal melanoma
Assigned to St Vincents Hospital Sydney Ltd · Expires 2025-07-02 · 1y expired
What this patent protects
Provided herein is a combination therapy and methods of using such combination therapy as a neoadjuvant therapy and/or an adjuvant therapy in uveal melanoma, inter alia to reduce the risk of metastasis and/or enucleation, and/or preserving eye function. Uveal melanoma (UM) is the…
USPTO Abstract
Provided herein is a combination therapy and methods of using such combination therapy as a neoadjuvant therapy and/or an adjuvant therapy in uveal melanoma, inter alia to reduce the risk of metastasis and/or enucleation, and/or preserving eye function. Uveal melanoma (UM) is the most common primary intraocular malignant tumor in adults. The protein kinase C (PKC) inhibitor, sotrastaurin, has been shown to have activity against certain PKC isototypes and has been shown to selectively inhibit the growth of uveal melanoma cells harboring GNAQ mutations by targeting PKC/ERK1/2 and PKC/NF-xB pathways.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.